Striatal opioid receptor availability is related to acute and chronic pain perception in arthritis: Does opioid adaptation increase resilience to chronic pain?

DOI:
10.1097/j.pain.0000000000000299

Citation for published version (APA):

Published in:
Pain

Citing this paper
Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights
Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy
If you believe that this document breaches copyright please refer to the University of Manchester’s Takedown Procedures [http://man.ac.uk/04Y6Bo] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.
Striatal opioid receptor availability is related to acute and chronic pain perception in arthritis: does opioid adaptation increase resilience to chronic pain?

Christopher A. Brown, Julian Matthews, Michael Fairclough, Adam McMahon, Elizabeth Barnett, Ali Al-Kaysi, Wael El-Deredy, Anthony K.P. Jones

Abstract
The experience of pain in humans is modulated by endogenous opioids, but it is largely unknown how the opioid system adapts to chronic pain states. Animal models of chronic pain point to upregulation of opioid receptors (OpR) in the brain, with unknown functional significance. We sought evidence for a similar relationship between chronic pain and OpR availability in humans. Using positron emission tomography and the radiotracer ¹¹C-diprenorphine, patients with arthritis pain (n = 17) and healthy controls (n = 9) underwent whole-brain positron emission tomography scanning to calculate parametric maps of OpR availability. Consistent with the upregulation hypothesis, within the arthritis group, greater OpR availability was found in the striatum (including the caudate) of patients reporting higher levels of recent chronic pain, as well as regions of interest in the descending opioidergic pathway including the anterior cingulate cortex, thalamus, and periaqueductal gray. The functional significance of striatal changes were clarified with respect to acute pain thresholds: data across patients and controls revealed that striatal OpR availability was related to reduced pain perception. These findings are consistent with the view that chronic pain may upregulate OpR availability to dampen pain. Finally, patients with arthritis pain, compared with healthy controls, had overall less OpR availability within the striatum specifically, consistent with the greater endogenous opioid binding that would be expected in chronic pain states. Our observational evidence points to the need for further studies to establish the causal relationship between chronic pain states and OpR adaptation.

Keywords: Pain, Arthritis, PET, Opioid, Striatum

1. Introduction
Chronic pain is frequently reported by patients with arthritis. However, there is no correlation between pain and structural joint damage in osteoarthritis (OA). The basis of variability between pathophysiology and pain outcomes is unknown. One possibility is natural variability in pain regulation within the central nervous system.

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

© 2015 International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.

November 2015 • Volume 156 • Number 11 www.painjournalonline.com

PAIN 156 (2015) 2267–2275
http://dx.doi.org/10.1097/j.pain.0000000000002599
cord ipsilateral to the site of injury. Stimulus-evoked translocation of delta-OpRs to neuronal plasma membranes may have evolved as part of a homeostatic mechanism to maintain control of nociceptive transmission. However, evidence for such a mechanism in humans is lacking.

Positron emission tomography (PET) receptor-binding studies enable assessment of the endogenous opioid system in humans through radiotracers that bind to OpRs, such as carbon-11-labelled diprenorphine \([{^{11}}C]-DPN\), an antagonist that binds equally well to mu-, delta-, and kappa-OpRs. Here, we measured OpR availability in patients with arthritis and healthy controls with \([^{11}}C]-DPN\) PET imaging to identify relationships between OpR availability and the level of perceived acute and chronic pain. Our analysis revealed associations between the striatum and the perception of both acute and chronic pain. We interpret our findings in relation to the hypothesis, supported by the aforementioned evidence from the animal literature, of adaptive upregulation of OpR-binding sites in chronic pain states.

### 2. Materials and methods

The research study was approved by Stockport NHS Research Ethics Committee (Reference O9/H1012/44) and permission was granted by ARSAC (radiation protection agency).

#### 2.1. Participants

Seventeen patients (12 females) and nine healthy control participants (3 females) were recruited into the study. All participants gave written informed consent. The characteristics of the participants are shown in Table 1. Patients were recruited from primary and secondary care in Greater Manchester, whereas healthy control participants were recruited from an existing database of research volunteers and from primary care in Greater Manchester. Fifteen participants had a diagnosis of OA, whereas 2 had a diagnosis of rheumatoid arthritis (RA). All patients had experienced chronic pain for at least the past 3 months. Patients with OA and RA fulfilled the American College of Rheumatology (ACR) criteria for the diagnosis of OA and RA. Control participants were experiencing any chronic pain or other recurrent health problems. Exclusion criteria for both groups included age of <35 years and medical records showing a history of neurological disorder, morbid psychiatric disorder (including major depression and anxiety-related disorders confirmed by a psychiatrist), organ failure, or cardiovascular disease. It was expected that patients would be recruited with subclinical levels of anxiety and depression that are normal for chronic pain populations.

Any patients taking opioid analgesic medication, of which there were 2, were asked to withdraw before scanning. The timing of this withdrawal was determined on a case-by-case basis, but was started no more than 2 weeks prior, and completed not later than 2 days prior, to each scanning session. Any paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) were withdrawn at least 24 hrs before scanning.

#### 2.2. MRI data acquisition and preprocessing

A T1-weighted MRI brain scan was acquired for the purpose of excluding structural abnormality, coregistration, and spatial normalization of PET images (see Supplementary Methods, available online as Supplemental Digital Content at http://links.lww.com/PAIN/A159). MRIs were segmented into white matter, gray matter, and cerebrospinal fluid using Statistical Parametric Mapping (SPM8; Wellcome Department of Imaging Neuroscience, Institute of Neurology, UCL, London, United Kingdom) running on MATLAB version 7.10 (The Mathworks Inc, Natick, MA).

#### 2.3. Questionnaire assessments

Patients (but not healthy controls) completed an assessment of clinical pain as experienced over the last week, before PET scanning. Clinical pain was measured using the short-form McGill Pain Questionnaire, which has subscales for sensory and affective pain.

#### 2.4. Positron emission tomography scans

A cannula was inserted into a radial artery of the nondominant forearm after a satisfactory modified Allen’s test and local anaesthesia, for sampling of arterial blood during the scan. An intravenous cannula was inserted into the dominant forearm for radiotracer injection.

Patients were scanned using a Siemens/CTI High Resolution Research Tomograph (HRRT; CTI/Siemens Molecular Imaging, Knoxville, TN) PET scanner at the Wolfson Molecular Imaging Centre, capable of 2.5 mm resolution. Participants were positioned supine with their transaxial planes parallel to the line intersecting anterior and posterior commissure (AC–PC line). Head position was measured and equated as best as possible in both PET sessions. Head movement during scanning was discouraged by applying gentle pressure to the nasion by means of a padded attachment to the head holder. Patients wore a customized neoprene cap with a reflective tool attached to the vertex that was used to continuously assess head motion using a Polaris Vicra infrared motion detector (Northern Digital, ON, Canada). Before further scanning, a 6-minute transmission scan was performed for attenuation correction, facilitated by a \[^{\text{18}}\text{Cs}\] transmission point source.

Regional cerebral blood flow (rCBF) was measured to allow for assessment of the relationship of \([^{11}}C]\)-DPN binding results to rCBF. After the transmission scan and immediately before the \([^{11}}C]\)-DPN scan, 510 to 645 MBq (target dose: 600 MBq) of

### Table 1

<table>
<thead>
<tr>
<th>Group characteristics.</th>
<th>Total, n</th>
<th>Females, n</th>
<th>Age, y</th>
<th>Weight, kg</th>
<th>DPN dose injected, MBq</th>
<th>H2O dose injected, MBq</th>
<th>Head motion</th>
<th>Intracranial pain ratings</th>
<th>Thermal pain threshold, W cm⁻²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arthritis patients</td>
<td>17</td>
<td>12</td>
<td>57.5 (12.1)</td>
<td>83.1 (21.0)</td>
<td>490.0 (62.3)</td>
<td>606.7 (22.3)</td>
<td>3.6 (3.3)</td>
<td>2.5 (2.0)</td>
<td>3.9 (1.5)</td>
</tr>
<tr>
<td>Healthy controls</td>
<td>9</td>
<td>3</td>
<td>45.4 (7.5)</td>
<td>78.8 (16.2)</td>
<td>505.0 (33.0)</td>
<td>583.4 (30.7)</td>
<td>1.6 (1.8)</td>
<td>1.5 (1.4)</td>
<td>4.0 (1.9)</td>
</tr>
<tr>
<td>Independent-sample</td>
<td>0.08</td>
<td>0.004</td>
<td>0.59</td>
<td>0.26</td>
<td>0.07</td>
<td>0.146*</td>
<td>0.18</td>
<td>0.76</td>
<td></td>
</tr>
</tbody>
</table>

Values are expressed as means (with standard deviation). Equal variances not assumed. All test are parametric t tests except for * indicating non-parametric Wilcoxon rank sum test. Italicized values indicate a statistically significant group effect.

DPN, diprenorphine.


Characteristics of $^{11}$C-[DPN] would be expected to change along with blood flow as the matrix (isotropic voxel size of 1.21875 mm$^3$) that could be accounted for decay of $^{11}$C. The fast frequency boundary was set to 0.02 s$^{-1}$ and the slow frequency boundary to 0.0008 s$^{-1}$. The slow frequency boundary was informed by 2 considerations: (1) the slowest possible kinetics of $^{11}$C-[DPN], which is limited by the physical decay constant of the isotope (0.0005663 s$^{-1}$), deriving from the half-life of $^{12}$C (20.4 minutes); (2) data evaluating the image quality, reproducibility, and reliability of $^{11}$C-[DPN] VD images across a range of slow frequency boundaries, which identified 0.0008 s$^{-1}$ as being superior to lower cutoffs that were closer to the decay constant of $^{11}$C. The spectra were spaced logarithmically and the magnitude was normalised so that the weighted columns summed to unity. Individual data points were weighted according to the reciprocal of the variance, as estimated from the frame duration over the total image concentration. A delay, which was fixed over the entire image volume, was estimated by fitting the same spectral analysis model to a time-activity curve (TAC) from regions of interest (ROI) over the entire image volume and varying the delay using a golden line search algorithm to determine the delay that minimised the weighted least squared error.

### 2.5. Derivation of arterial input function

The input function of parent $^{11}$C-[DPN] in arterial blood plasma was derived as follows. To obtain the time-course of whole-blood radioactivity over time, the continuous blood data from the first 10 minutes of the $^{11}$C-[DPN] scan was firstly calibrated against radioactivity measured in discrete blood samples (using a well counter) at corresponding time points. This initial time-course was then spliced with an interpolation of the discrete blood radioactivity data over the remainder of the scan to obtain the full time-course. From the discrete blood samples, the plasma-over-blood ratio was calculated and linearly fitted. Using the radiolabelled water (H$_2^{15}$O) was administered, using an automatic radio water generator (HIDEX Inc, Turku, Finland) (see Supplementary Methods, available online as Supplemental Digital Content at http://links.lww.com/PAIN/A159). This was followed by an intravenous smooth bolus subpharmacological tracer dose of $[^{151}]$-DPN injected over 20 seconds, followed by a 20-second saline flush. $^{11}$C-[DPN] was initially synthesized in situ at the Wolfson Molecular Imaging Centre using the methylation method. Characteristics of $^{11}$C-[DPN] doses are shown in Supplementary Table 1 (available online as Supplemental Digital Content at http://links.lww.com/PAIN/A159). A 90-minute continuous acquisition in list mode followed injection (see Supplementary Methods, available online as Supplemental Digital Content at http://links.lww.com/PAIN/A159).

For both the $^{11}$C-[DPN] and H$_2^{15}$O scans, continuous measurements of the radioactivity in arterial blood were conducted, and further intermittent discrete arterial blood sampling took place for cross-calibration and to determine the partition of blood radioactivity between plasma and whole blood (erythrocytes) (see Supplementary Methods. available online as Supplemental Digital Content at http://links.lww.com/PAIN/A159).

### 2.6. $^{11}$C-[DPN] and H$_2^{15}$O PET image reconstruction

Positron emission tomography images were reconstructed to a 256 × 256 × 207 matrix (isotropic voxel size of 1.21875 mm$^3$) using an iterative Ordinary Poisson Ordered Subset Expectation Maximization algorithm (OP-OSEM; 12 iterations). The reconstruction was performed using the HRRT user community software with the default resolution kernel. After reconstruction, the dynamic images were trimmed, calibrated, and stored as Analyze 7.5 formatted images. The calibration factor was determined using a uniform head-sized phantom, which is scanned periodically (~every 2 weeks).

### 2.7. Derivation of $^{11}$C-[DPN] volume of distribution and K$_{1_{DPN}}$

Parametric images of the $^{11}$C-[DPN] volume of distribution (VD$_{DPN}$) and the $^{11}$C-[DPN] rate of uptake from blood to tissue (K$_{1_{DPN}}$) were calculated using spectral analysis and implemented using the nonnegative least squares algorithm (conventional spectral analysis). Inputs to this analysis were the dynamic PET images and the arterial input function, both uncorrected for decay of $^{11}$C. Kinetic modelling of $^{11}$C-[DPN] using spectral analysis is based on a compartmental model in which delivery of the radiotracer (represented by the parameter K$_{1_{DPN}}$) to brain tissues is modelled separately to specific binding (represented by VD$_{DPN}$) and nonspecific binding (to other cellular molecules). However, K$_{1_{DPN}}$ would be expected to change along with blood flow as a result of differences in pain state. In particular, delivery effects may act as a confounder of the positive relationship between chronic pain perception and radiotracer binding: it would be expected that chronic pain would increase blood flow to the brain and increase the concentration of radiotracer in regions of interest. We controlled for radiotracer delivery effects within the statistical analysis by removing any variance in VD$_{DPN}$ that could be accounted for by global K$_{1_{DPN}}$ (the parameter estimating radiotracer delivery). Although reliance on global values of K$_{1_{DPN}}$

### 2.8. Derivation of regional cerebral blood flow

Parametric images of the H$_2^{15}$O kinetic parameter K$_{1_{H2O}}$ (mL/min·1·mL$^{-1}$), a measure of rCBF, were obtained using a one-tissue compartment model in which K$_{1_{H2O}}$ is the rate of uptake of H$_2^{15}$O from blood to brain. An input function of total radioactivity in whole blood was used, which was calculated by scaling the continuous blood data, as with the $^{11}$C-[DPN] blood data. Reconstructed H$_2^{15}$O PET images were initially smoothed with a 4-mm FWHM Gaussian kernel before kinetic modelling using the Generalized Linear Least Squares (GLLS) algorithm.

### 2.9. VD$_{DPN}$, K$_{1_{DPN}}$ and K$_{1_{H2O}}$ image preprocessing

Preprocessing of parametric images was performed using SPM8 (Statistical Parametric Mapping: Wellcome Department of Cognitve Neurology, London, United Kingdom). Each PET image were coregistered onto the corresponding T1-weighted MRI image using rigid body transformation derived from the normalized mutual information measure of image matching. Next, MRI images were spatially normalised into the International Consortium for Brain Mapping (ICBM) standardised space (Montreal Neurological Institute, Montreal, Canada) using nonlinear basis functions, with the same transformation characteristics then applied to the coregistered parametric PET images.

### 2.10. Calculation of global K$_{1_{DPN}}$

Kinetic modelling of $^{11}$C-[DPN] using spectral analysis is based on a compartmental model in which delivery of the radiotracer (represented by the parameter K$_{1_{DPN}}$) to brain tissues is modelled separately to specific binding (represented by VD$_{DPN}$) and nonspecific binding (to other cellular molecules). However, K$_{1_{DPN}}$ would be expected to change along with blood flow as a result of differences in pain state. In particular, delivery effects may act as a confounder of the positive relationship between chronic pain perception and radiotracer binding: it would be expected that chronic pain would increase blood flow to the brain and increase the concentration of radiotracer in regions of interest. We controlled for radiotracer delivery effects within the statistical analysis by removing any variance in VD$_{DPN}$ that could be accounted for by global K$_{1_{DPN}}$ (the parameter estimating radiotracer delivery). Although reliance on global values of K$_{1_{DPN}}$
might not be ideal, we determined that “regional” $K_{1\text{DPN}}$ did not correlate with regional $VD_{\text{DPN}}$ as a result. The weighted average of $K_{1\text{DPN}}$ values in gray matter across the whole brain were therefore calculated for each scan. $K_{1\text{DPN}}$ values in gray matter were initially identified using a gray matter mask on $K_{1\text{DPN}}$ images.

2.11. Analysis of head motion data

Head motion is a nuisance variable that could potentially cause unwanted between-subject and/or between-group variability in $VD_{\text{DPN}}$ values. We therefore controlled for head motion in statistical tests. Quantitative head motion data were collected from the Vicra system, but the raw data were considered unreliable due to the observation that the head was able to move to a small extent within the neoprene cap worn by the participant to mount the head motion sensors. Analysis of head motion data was therefore performed in a semiquantitative manner, in that it relied on some qualitative assessment to achieve an ordinal score of total motion.

Head motion data consisted of both translational and rotational movements, each represented by 3 separate time-courses for each dimension of movement. Using visual inspection of these data, each $[^{11}]$C-DPN scan was scored separately for (1) intra-scan motion taking place over 2 or more dynamic frames of the PET data, (2) motion taking place between the transmission scan and the $[^{11}]$C-DPN scan, (3) the magnitude of infrequent intra-frame discrete motion events, and (4) the magnitude of frequent intra-frame motion events (Supplementary Table 2, available online as Supplemental Digital Content at http://links.lww.com/PAIN/A159). Separate scales were used to score each item for the degree of motion observed to account for the likely impact of that motion on the quality of the PET data. Movements of less than 1 mm translation, or 1 degree of rotation (which roughly equates to a 1-mm movement of superficial cortical regions), were considered inconsequential due to the resolution of the PET camera at 2.5 mm. Intraframe motion events were scored higher (and higher again with greater frequency) than motion events spanning across 2 or more dynamic frames of PET data, because the latter were at least partially corrected during reconstruction. Scores for each type of motion were summed to create an overall motion severity score for each scan. Two researchers scored the head motion data independently, and mean values were generated for these scores.

2.12. Assessment of acute thermal pain threshold

The order of PET and thermal pain threshold assessments were randomised between participants and occurred on different days within 4 weeks of each other. Acute pain was induced using a CO$_2$ laser (150-millisecond duration, beam diameter of 15 mm), which specifically activates nociceptors in the skin, applied to the dorsal surface of the subjects’ right forearm. Between stimuli, the laser was moved randomly over an area $3 \times 5$ cm to avoid habituation, sensitization, or skin damage, with stimuli occurring at 10-second intervals. Subjects wore protective laser safety goggles.

To determine pain threshold, the Method of Levels was used. Participants were instructed to attend to the intensity of each laser stimulus and to rate it using a 0 to 10 numerical rating scale (NRS), which was anchored such that a level 4 indicated pain threshold, 7 indicated moderate pain, and 10 indicated unbearable pain. Laser stimuli were gradually increased in steps of 0.3 W cm$^{-2}$ stimulus irradiance, from 0 up to a subjective intensity of 7 of 10, and were repeated 3 times. Pain threshold was considered as the mean stimulus energy, over the first 3 ramps, required to elicit a response of 4 of 10.

2.13. Statistical analyses

Statistical analyses were conducted on $[^{11}]$C-DPN $VD$ images on a voxel-by-voxel basis across the whole brain using SPM8 software. Before whole-brain analyses, smoothing of images was performed using a 3-dimensional Gaussian kernel of 8 mm.

Whole-brain regression analyses were conducted within the patient group ($n = 17$) to identify regions correlating with sensory and affective dimensions of pain (Short-Form McGill Pain Questionnaire, sensory and affective subscales). In all tests, a number of covariates controlled for nuisance variables: subject age (years), subject sex (binary), subject weight (kg), $[^{11}]$C-DPN dose injected (MBq), global $K_{1\text{DPN}}$ (min$^{-1}$), head motion scores, and mean NRS ratings of pain reported across the whole scan. For all whole-brain comparisons, results are reported at uncorrected probability thresholds of $P < 0.001$ with a minimum cluster size of 50 voxels, and results are considered statistically significant after voxel-level correction for multiple comparisons using the familywise error rate set to 0.05.

Further analyses were conducted on ROIs whose values were obtained as follows. From each scan, $VD_{\text{DPN}}$ values were extracted from ROIs in which suprathreshold clusters (after familywise error correction) were found. Most ROIs were defined by anatomical labels within a previously published probabilistic atlas of the human brain, except for the periaqueductal gray (PAG) whose ROI was constructed from 3 overlapping 6-mm spheres along the central aqueduct (in mm, 0 $- 24 - 4; 0 - 26 - 6; 0 - 29 - 8$) as done in previous work. A weighted average of $VD_{\text{DPN}}$ values within ROIs was calculated. $K_{1\text{DPN}}$ and $K_{1\text{H}_{2}O}$ values were obtained from ROIs in the same way.

Region of interest analyses sought to identify group differences and correlations with pain threshold. Firstly, ROIs from the patient ($n = 17$) and healthy control ($n = 8$) groups were statistically compared using an independent-sample $t$ test with significance threshold of $P < 0.05$, after corrections had been made to the mean $VD_{\text{DPN}}$ within each ROI by controlling for variance related to nuisance variables. The same nuisance variables were used as in the whole-brain analysis described above. Secondly, ROI data from each group separately, and also from the pooled data across both groups, were correlated with pain threshold as assessed by the acute laser stimuli. Mean ROI values were first corrected for nuisance variables as described above, with an additional variable being each subjects’ 0 to 10 NRS rating of acute laser pain intensity. Pearson’s product–moment correlation coefficient was obtained, and results were considered statistically significant at $P < 0.05$.

To test whether rCBF explained any of the variances in the $VD_{\text{DPN}}$ data after correction for $K_{1\text{DPN}}$, mean $K_{1\text{H}_{2}O}$ within ROIs were tested for correlation with both mean $VD_{\text{DPN}}$ within the same ROIs, and predictor variables of interest showing statistically significant relationships with $VD_{\text{DPN}}$ (namely, McGill sensory and affective pain scores and acute pain threshold), $K_{1\text{H}_{2}O}$ for the patient ($n = 14$) and control ($n = 8$) groups were also compared by independent-sample $t$ test in the same way as for the $VD_{\text{DPN}}$ data.

3. Results

3.1. Participant characteristics and group comparisons

Data for group comparisons of sex, age, weight, radiotracer doses, intrascan pain ratings, head motion during scanning, and
acute laser thermal pain thresholds are shown in Table 1. There was a larger proportion of females in the patient group (that was not statistically significant), and patients were significantly older than healthy controls. The dose of [11C]-DPN injected, and the weight of participants (which may impact on radiotracer concentrations reaching the brain), did not significantly differ between groups, whereas the dose of water injected to assess rCBF was overall greater in patients than controls. On average, patients reported being in greater pain than controls during scanning, but the results were not statistically significant suggesting that efforts to make patients comfortable were at least partially successful. However, patients on average showed more than twice as much head motion during scanning, although this did not reach statistical significance compared with the healthy group. Finally, while patients may scale pain differently because of their previous experience of chronic pain, we found no evidence of a difference in pain thresholds between groups.

3.2. Effect of chronic pain perception on opioid receptor availability

Whole-brain SPM regression analysis (Figures 1A and B, Supplementary Table 3, available online as Supplemental Digital Content at http://links.lww.com/PAIN/A159) revealed that in patients with chronic pain, McGill sensory pain scores, for their chronic pain over the previous week, was significantly and positively correlated with OpR availability at the cluster level in the caudate nucleus, continuous with the nucleus accumbens and the subcallosal area. The right mid-insula showed the same effect at just below the level of significance. As the data were corrected for head motion in this statistical model, the greater VD values could not be ascribed to this factor. Also, having corrected for delivery effects in the analysis using the kinetic parameter K1, the mean VD values were not correlated with rCBF in the caudate ($r = 0.27$, $P = 0.35$) nor was rCBF related to chronic pain perception (Table 2), suggesting that the relationship between chronic pain perception and VD in the region of interest was not driven by greater blood flow in patients experiencing greater chronic pain.

As confirmation that the main result in the caudate was not related to modification of the endogenous opioid system by recent use of opioid medication, ROI analysis on the whole caudate was found to be comparable for the whole patient group ($n = 17$, $r = 0.691$, $P = 0.002$) and for a restricted patient group that excluded those withdrawn from opioid medication for the purpose of scanning ($n = 15$, $r = 0.887$, $P = 0.005$).

Analysis on further ROIs (putamen, insula, thalamus, and PAG, Table 2), in which mean VD values were taken over each ROI bilaterally, also revealed significant associations between chronic pain perception and OpR availability, suggesting a broad relationship between chronic pain and OpR availability across a network of brain regions expressing OpRs, including those involved with descending inhibition of nociception. Testing the same ROIs against patients’ affective pain perception (McGill affective pain scores) yielded a significant positive relationship within the caudate nucleus and subcallosal area only.

3.3. Opioid receptor availability correlation with pain threshold

Opioid receptor availability was found positively correlate with laser heat pain threshold in both the caudate and subcallosal area (Table 2), with the strongest effect in the caudate (Figure 1C).

Figure 1. Relationship of [11C]-DPN binding to chronic pain perception and acute pain thresholds. The VD, as a proxy of [11C]-DPN binding, was adjusted for a number of nuisance variables in each analysis (see Methods). (A) Whole-brain SPM regression analysis of McGill sensory pain scores as a predictor of [11C]-DPN binding (patients only, $n = 17$). Images are displayed at a voxel threshold of $P < 0.001$ uncorrected and a cluster threshold equating to the size of the significant cluster. (B) For illustrative purposes, subsequent extraction of mean VD values from the caudate nucleus was corrected for the same nuisance variables and plotted against McGill sensory pain scores. (C) Pain threshold (laser energy in $\text{W} \cdot \text{cm}^{-2}$ required to elicit the lowest pain sensation) regressed on VD values (mean across all voxels in the caudate ROI) after correction for nuisance variables. Regression line illustrates fits for the pooled data across groups (patients and controls, $n = 26$). ROI, region of interest; VD, volume of distribution.
Effects were close to significance in the putamen and insula but not in nucleus accumbens. The strength of the effect was also greater (for caudate and the subcallosal area) in the pooled data over both groups, with individual groups showing weaker relationships (leading to effects above the threshold of significance in the subcallosal area) consistent with the fewer degrees of freedom when considering individual groups.

Pain thresholds were also related to rCBF in the caudate nucleus, but on further assessment rCBF was not related to diprenorphine VD values in the caudate ($r = 0.21, P = 0.36$), and so the relationship between OpR binding and rCBF results remains obscure.

### 3.4. Group differences in opioid receptor availability

Group comparison of mean VD values in ROIs revealed overall lower OpR availability in the caudate nucleus in patients relative to controls (Table 2). Although OpR availability was also lower in patients in the subcallosal area and nucleus accumbens, these effects did not reach significance. There were no group differences in any other ROIs, suggesting that these results are specific to the ventral striatum. There were no group differences in rCBF in the caudate nucleus.

### 4. Discussion

Three key findings emerge from this study: Firstly, the perception of higher levels of chronic pain within the arthritis group was related to greater OpR availability across pain-modulatory regions of the basal ganglia, insula, and PAG, and particularly strongly within the caudate, nucleus accumbens, and subcallosal area. This is the first time this has been reported in patients with arthritic pain. The result is consistent with the hypothesis of upregulation of receptor sites in those experiencing greater chronic pain.

Secondly, OpR availability in the caudate was positively associated with acute thermal pain threshold (in both patients and controls), supporting the view that upregulation of OpRs in the striatum is adaptive in acting to dampen pain perception. Thirdly, overall caudate OpR availability was reduced in patients with arthritis relative to healthy controls, consistent with greater release of endogenous opioid peptides and consequent occupation of OpR-binding sites in the arthritis group. Our analyses were strengthened by controlling for radiotracer delivery effects and head motion, 2 factors that are likely to be both responsive to pain states and have an influence on PET radioligand results.

### 4.1. OpR availability in chronic pain

The positive relationship between OpR availability and recent chronic pain perception could result either from a greater density of OpRs on neuronal cellular membranes (eg, due to increased trafficking or upregulation), reduced opioid “tone” (reduced release of endogenous opioid peptides resulting in reduced occupation of OpRs), or both. With single scans, it is not possible to directly measure opioid tone and OpR density independently. However, opioid “tone” is highly dependent on the current pain state, as illustrated by the fact that induction of acute pain for a short time during PET scanning procedures can be enough to cause a reduction in OpR availability as a result of endogenous opioid release and competitive binding to OpRs.

Yet, our data showing a positive association between OpR availability and previous chronic pain perception was statistically independent of intrascan pain perception. This does not favour the explanation that variability in the concentration of endogenous opioid peptides, released due to intrascan pain, were causing the positive correlation between OpR availability and previous chronic pain state.

Our analysis shows that the variances in OpR availability in the caudate nucleus explained by acute pain threshold were present in both patients with chronic pain and healthy controls. These variances can therefore be explained by natural variability in OpR density that is independent of the presence of arthritic disease and chronic pain symptoms. A greater density of OpRs would be expected to increase the sensitivity of postsynaptic neurons to opioid-mediated inhibition in response to pain, thereby increasing “gain” in the system.

In animals, delta- and kappa-Ops in the brain and spinal cord were upregulated in response to mu-Ops agonism. For mu-Ops, there is only evidence of upregulation in

---

Table 2

| Table 2: Statistics relating to random and fixed effect analyses on ROIs. |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|
|                                | McGill sensory pain | McGill affective pain | Acute pain threshold | Group |
|                                | Arthritis patients | Arthritis patients | Groups pooled | Arthritis patients | Healthy controls | Patients vs controls |
|                                | r      | P      | r      | P      | r      | P      | r      | P      | r      | P      |
| Diprenorphine data             |        |        |        |        |        |        |        |        |        |        |
| Caud                           | 0.641  | 0.002  | 0.587  | 0.013  | 0.596  | 0.002  | 0.572  | 0.021  | 0.735  | 0.024  | -2.107 | 0.047 |
| Subcal                         | 0.697  | 0.003  | 0.563  | 0.002  | 0.459  | 0.035  | 0.49   | 0.056  | 0.399  | 0.137  | -1.728 | 0.098 |
| NuAcc                          | 0.691  | 0.002  | 0.463  | 0.016  | 0.300  | 0.146  | 0.431  | 0.096  | 0.044  | 0.111  | -1.452 | 0.160 |
| Ins                            | 0.563  | 0.007  | 0.284  | 0.269  | 0.377  | 0.063  | 0.454  | 0.077  | 0.247  | 0.521  | -1.648 | 0.113 |
| Puta                           | 0.567  | 0.018  | 0.197  | 0.449  | 0.382  | 0.060  | 0.476  | 0.063  | 0.294  | 0.598  | -1.770 | 0.090 |
| Thal                           | 0.601  | 0.011  | 0.346  | 0.174  | 0.301  | 0.144  | 0.244  | 0.363  | 0.427  | 0.252  | -1.258 | 0.221 |
| ACC                            | 0.454  | 0.067  | -0.029 | 0.912  | 0.135  | 0.520  | 0.397  | 0.128  | 0.343  | 0.193  | -0.976 | 0.339 |
| PAG                            | 0.561  | 0.019  | -0.030 | 0.910  | 0.136  | 0.516  | 0.075  | 0.783  | 0.275  | 0.474  | -0.445 | 0.660 |
| Water data                     |        |        |        |        |        |        |        |        |        |        |        |        |
| Caud                           | 0.282  | 0.329  | 0.208  | 0.475  | 0.524  | 0.012  | 0.314  | 0.274  | 0.701  | 0.053  | -1.013 | 0.339 |

Significant effects are italicised.

ACC, anterior cingulate cortex; Caud, caudate nucleus; Ins, insula; NuAcc, nucleus Accumbens; P, probability of incorrectly rejecting the null hypothesis; PAG, periaqueductal gray; Puta, putamen; r, Pearson’s product moment correlation coefficient; Subcal, subcallosal area; Thal, thalamus.
response to “reduced” neurotransmitter binding, just as the normal adaptation to “greater” binding (eg, in response to morphine) is receptor downregulation. This may account for the greater antinoceptive effects of delta-selective agonists than nonselective agonists in chronic pain states. Together, this evidence implies that delta- and kappa-OpiR upregulation would be an expected consequence of chronic pain states. Given that [(11)C]-DPN is nonselective to OpiR subtypes, detection of such an upregulatory response is facilitated and may explain why studies using mu-selective ligands have not detected this mechanism.

Bringing this together, the most likely explanation for our findings is that there is an adaptive upregulation of OpiRs in response to chronic pain and that in general greater OpiR binding is associated with higher pain threshold and therefore greater pain resilience.

4.2. Group differences

The finding of overall lower OpiR availability in patients vs controls may be a result of competition for OpiR binding by the release of endogenous ligands as a result of pain being experienced during scanning, and possibly the recycling of receptors as a direct result of this. This finding is consistent with previous studies; reduced OpiR availability in the human brain has been associated with RA, peripheral neuropathic pain, and fibromyalgia. However, considering these earlier studies, it is surprising that we did not find group differences across more widespread brain regions, with results being restricted to the striatum. It is possible that our study is underpowered to detect differences between groups there are poorly balanced for age and sex. However, patients in our study were also made as comfortable as possible during scanning. The activity-dependent nature of pain in many patients with OA may mean that patients were able to achieve a greater level of comfort inside the scanner that has been possible in patients from these previous studies whose pain is likely to persist when at rest. As shown in Table 1, although a small number of patients did experience some discomfort that led to higher mean and variance in intrascan pain scores in the patient group relative to controls, the ratings are still within the nonpainful range.

However, it has been unclear whether findings of lower OpiR availability in patients with chronic pain compared with pain-free control subjects reflect greater vulnerability to chronic pain states (ie, reduced OpiR density resulting in reduced ability to dampen pain perception through opioidergic inhibition) or are merely a consequence of greater synaptic concentrations of endogenous opioids, released in response to pathological nociception, that compete with the same binding sites as opioid radiotracers. Our findings suggesting upregulation of OpiRs in response to chronic arthritic pain clarify that the latter explanation for reductions in OpiR availability in chronic pain states is the most likely and that there is increased release of endogenous opioid peptides in chronic arthritic pain.

4.3. Striatal mechanisms in chronic pain perception

The striatal dopamine and opioid systems have previously been shown to be abnormal in chronic pain syndromes. Patients with fibromyalgia and orofacial pain syndromes have an abnormal dopamine response to pain in the caudate and putamen. Furthermore, there is evidence of increased gray matter density in the striatum in a number of chronic pain conditions including fibromyalgia, chronic low back pain, and chronic vulvar pain. It is not yet clear how these abnormalities relate to the endogenous opioid system or to pain perception. Abnormalities in both dopaminergic and opioidergic neurotransmission in the striatum in patients with chronic pain might reflect motivational and motor processes such as the learning or expression of conditioned responses to pain. The ventral striatum is a region commonly associated with signalling rewarding outcomes and mediating reinforcement of appetitive behaviour. However, it is also commonly activated during anticipation of pain stimuli, particularly the caudate nucleus. Pavlovian prediction learning and evaluation has been associated with the “limbic loop,” including the ventral striatum, the basolateral amygdala, and the orbitofrontal cortex. The nucleus accumbens, in particular, brings evaluative information from the orbitofrontal cortex and amygdala to bear on performance by selectively gating information projecting to basal ganglia output nuclei. The above networks are involved with the generation of prediction errors for rewarding and aversive stimuli. However, prediction error signals in the nucleus accumbens have been specifically associated with Pavlovian conditioning, whereas prediction errors required for instrumental conditioning involve the putamen.

There is also evidence for a relationship between dopamine receptor binding in the ventral striatum (nucleus accumbens) with affective responses to pain. Ventral striatal reward mechanisms may therefore be directly implicated in driving the affective component of pain. However, our data showing a stronger correlation of OpiR availability with the sensory than the affective components of pain cast doubt on this hypothesis and suggest that the ventral striatum may have a more general motivational function in driving behavioural responses to pain. This is consistent with previous work demonstrating that stimulation of the caudate in monkey reduces behavioural reactivity to acute pain.

5. Conclusions

Our data are consistent with an upregulation of OpiRs in response to chronic pain in humans, a hypothesis first identified from animal research and suggested to be part of a homeostatic mechanism that dampens pain perception. This is the first observational evidence consistent with this hypothesis in humans, supported by a correlation between OpiR availability and pain resilience (greater pain threshold) in the caudate nucleus. Longitudinal studies are required to identify whether failure to adequately upregulate OpiRs in response to chronic pain may be a risk factor for a more extreme and/or refractory phenotype. Further sequential studies are needed to examine the benefits and pitfalls of current therapeutic approaches to chronic pain in terms of their effects on OpiR availability in the brain and the potential for increasing resilience to developing chronic pain from the outset.

Conflict of interest statement

The authors have no conflicts of interest to declare.

The study was funded by a project grant from the Medical Research Council (Grant Reference G0800522) in the United Kingdom.

Acknowledgements

We extend our gratitude to all staff at the Wolfson Molecular Imagine Centre who were essential for the success of this project,
in particular Professor Karl Herholz and Dr Peter Talbot who helped with the initial concept and design, and the radiographers, radiochemists, and blood laboratory for helping to implement the study. We also wish to thank the consultant anaesthetists who aided in the collection of blood data, and a special thanks to our research nurse Ann Lenton who was crucial for patient recruitment.

Appendix A. Supplemental Digital Content

Supplemental Digital Content associated with this article can be found online at http://links.lww.com/PAIN/A159.

Article history:
Received 19 February 2015
Received in revised form 18 June 2015
Accepted 6 July 2015
Available online 14 July 2015

References

Copyright © 2015 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.